Included in the formulation
АТХ:C.01.E.B Other drugs for the treatment of heart disease
Pharmacodynamics:Selectively competitively blocks bradykinin B2-receptors, binding endogenous bradykinin with bradykinin B2-receptors, which prevents the pharmacological action of bradykinin.
Pharmacokinetics:After subcutaneous administration, the maximum concentration in the blood plasma is reached after 30 minutes. The connection with plasma proteins is 44%.
Metabolism in the liver.
Half-life is 1-2 hours. Elimination by the kidneys (up to 90%) and with feces (up to 10%).
Indications:It is used for the symptomatic treatment of acute attacks of hereditary angioedema in adults with a deficiency of the C1-esterase inhibitor.
XIX.T66-T78.T78.3 Angioedema
Contraindications:Individual intolerance, age over 65 years, children under 18 years.
Carefully:An exacerbation of coronary heart disease, unstable angina, a condition after a stroke for 1 of the week.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Subcutaneously in the form of a solution with a concentration of 30 mg / 3 ml in the abdomen, no more than 3 times a day with an interval of at least 6 hours.The duration of treatment is determined individually.
The highest daily dose: 90 mg.
The highest single dose: 30 mg.
Side effects:Central and peripheral nervous system: asthenia, headache, dizziness.
Respiratory system: asthma, cough, pharyngitis, nasal congestion.
The system of hematopoiesis: increased prothrombin time.
Digestive system: increase in body weight.
Dermatological reactions: erythema, itchy skin.
Urinary system: proteinuria, hyperuricemia.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction: Not described.
Special instructions:Treatment of patients with laryngeal edema is carried out only in a hospital.